# Processa Pharmaceuticals, Inc.: Form 10-Q/A for the period ended Jun 30, 2013

- Company: [Processa Pharmaceuticals, Inc.](/companies/pcsa.md) (CIK 1533743)
- Form: 10-Q/A
- Filed: 2013-09-06
- Accepted by EDGAR: Sep 6, 2013, 16:14 ET
- Period: 2013-06-30
- Accession: 0001393905-13-000498
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1533743/000139390513000498/hwux_10qa.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1533743/000139390513000498/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-04-01 to 2013-06-30 | $97.3k | us-gaap:Revenues |
| Revenue | 6 months, 2013-01-01 to 2013-06-30 | $116.5k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-04-01 to 2013-06-30 | $61.5k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2013-01-01 to 2013-06-30 | $73.7k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2013-04-01 to 2013-06-30 | $35.8k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2013-01-01 to 2013-06-30 | $42.8k | us-gaap:GrossProfit |
| Research and development | 3 months, 2013-04-01 to 2013-06-30 | $63.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2013-01-01 to 2013-06-30 | $135.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2013-04-01 to 2013-06-30 | $665.6k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2013-01-01 to 2013-06-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2013-04-01 to 2013-06-30 | −$33.8k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2013-01-01 to 2013-06-30 | −$49.6k | us-gaap:InterestExpense |
| Net income | 3 months, 2013-04-01 to 2013-06-30 | −$726.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2013-01-01 to 2013-06-30 | −$1.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-04-01 to 2013-06-30 | −$0.34 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2013-01-01 to 2013-06-30 | −$0.79 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2013-01-01 to 2013-06-30 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2013-01-01 to 2013-06-30 | $7.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-06-30 | $629.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-06-30 | $937.8k | us-gaap:AssetsCurrent |
| Total assets | at 2013-06-30 | $3.5m | us-gaap:Assets |
| Current liabilities | at 2013-06-30 | $2.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-06-30 | $2.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-06-30 | $1.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2013-06-30 | 7,029,397 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1533743/000139390513000498/hwux_10qa.htm

Filed Sep 6, 2013.
Source: SEC EDGAR, the filing index for accession 0001393905-13-000498. Last ingested by Listed: Nov 14, 2026, 23:30 ET. No prices; not investment advice.
